FATE THERAPEUTICS INC. - COMMON STOCK

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 11月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

09 11月 2024 13:30:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

08 11月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

04 11月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 10月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

12 9月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

13 8月 2024 16:05:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 8月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

31 7月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

02 7月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

04 6月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

29 5月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

09 5月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

09 5月 2024 08:30:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates

06 5月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

03 5月 2024 16:30:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

22 4月 2024 16:30:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference

03 4月 2024 08:00:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

02 4月 2024 16:01:00 条件 Nasdaq GlobeNewswire

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

19 3月 2024 08:44:41 条件 Nasdaq GlobeNewswire